{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:22:27Z","timestamp":1789647747216,"version":"4.0.0"},"reference-count":101,"publisher":"Elsevier","isbn-type":[{"value":"9780128167540","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2016-77758-R"],"award-info":[{"award-number":["SAF2016-77758-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003451","name":"Euskal Herriko Unibertsitatea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004233","name":"Universitat Polit\u00e8cnica de Val\u00e8ncia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["IT-901\/16"],"award-info":[{"award-number":["IT-901\/16"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["T747-13"],"award-info":[{"award-number":["T747-13"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.irn.2019.06.013","type":"book-chapter","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T08:22:36Z","timestamp":1563438156000},"page":"259-279","source":"Crossref","is-referenced-by-count":26,"title":["Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia"],"prefix":"10.1016","author":[{"given":"Sergio","family":"Vegas-Suarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Paredes-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asier","family":"Aristieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose V.","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Miguelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ugedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2019.06.013_bb0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"2","key":"10.1016\/bs.irn.2019.06.013_bb0015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective \u03b1-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: Potential therapy for Parkinson's disease","volume":"26","author":"Alarc\u00f3n-Ar\u00eds","year":"2018","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","article-title":"Parallel organization of functionally segregated circuits linking basal ganglia and cortex","volume":"9","author":"Alexander","year":"1986","journal-title":"Annual Review of Neuroscience"},{"issue":"8","key":"10.1016\/bs.irn.2019.06.013_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042652","article-title":"The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats","volume":"7","author":"Aristieta","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.irn.2019.06.013_bb0030","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00213-013-3333-0","article-title":"Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration","volume":"231","author":"Aristieta","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2019.06.013_bb0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nbd.2016.02.003","article-title":"Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats","volume":"89","author":"Aristieta","year":"2016","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2019.06.013_bb0040","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.neuropharm.2013.11.024","article-title":"Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in l-DOPA-treated rats","volume":"79","author":"Azkona","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2019.06.013_bb0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.brainres.2008.03.060","article-title":"Dystrophic serotonergic axons in neurodegenerative diseases","volume":"1217","author":"Azmitia","year":"2008","journal-title":"Brain Research"},{"issue":"4","key":"10.1016\/bs.irn.2019.06.013_bb0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2019.06.013_bb0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neuroimage.2018.08.016","article-title":"Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates","volume":"183","author":"Beaudoin-Gobert","year":"2018","journal-title":"NeuroImage"},{"issue":"6","key":"10.1016\/bs.irn.2019.06.013_bb0060","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","article-title":"The Function of \u03b1-synuclein","volume":"79","author":"Bendor","year":"2013","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/bs.irn.2019.06.013_bb0065","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1468-1331.2010.03274.x","article-title":"Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease\u2014A [123I]-ADAM SPECT study","volume":"18","author":"Beucke","year":"2011","journal-title":"European Journal of Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2019.06.013_bb0070","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"10","key":"10.1016\/bs.irn.2019.06.013_bb0075","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2019.06.013_bb0080","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1445-5994.2008.01747.x","article-title":"Persistent dystonia induced by fluoxetine","volume":"38","author":"Bilen","year":"2008","journal-title":"Internal Medicine Journal"},{"issue":"6","key":"10.1016\/bs.irn.2019.06.013_bb0085","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1460-9568.2012.08202.x","article-title":"Serotonin transporter inhibition attenuates l -DOPA-induced dyskinesia without compromising l -DOPA efficacy in hemi-parkinsonian rats","volume":"36","author":"Bishop","year":"2012","journal-title":"European Journal of Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1016\/bs.irn.2019.06.013_bb0095","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"Journal of Neural Transmission"},{"issue":"3","key":"10.1016\/bs.irn.2019.06.013_bb0100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/mds.10343","article-title":"Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications","volume":"18","author":"Calon","year":"2003","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1016\/bs.irn.2019.06.013_bb0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00702-007-0015-2","article-title":"Loss of thalamic serotonin transporters in early drug-na\u00efve Parkinson's disease patients is associated with tremor: An [(123)I]beta-CIT SPECT study","volume":"115","author":"Caretti","year":"2008","journal-title":"Journal of Neural Transmission (Vienna, Austria: 1996)"},{"issue":"7","key":"10.1016\/bs.irn.2019.06.013_bb0110","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2019.06.013_bb0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neuropharm.2016.07.025","article-title":"Monoamine transporter contributions to l -DOPA effects in hemi-parkinsonian rats","volume":"110","author":"Conti","year":"2016","journal-title":"Neuropharmacology"},{"issue":"9916","key":"10.1016\/bs.irn.2019.06.013_bb0120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/bs.irn.2019.06.013_bb0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.brainresbull.2017.05.014","article-title":"Fluvoxamine maleate effects on dopamine signaling in the prefrontal cortex of stressed Parkinsonian rats: Implications for learning and memory","volume":"132","author":"Dall\u00e9","year":"2017","journal-title":"Brain Research Bulletin"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behavioural Brain Research"},{"issue":"4","key":"10.1016\/bs.irn.2019.06.013_bb0135","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","article-title":"Tremor in Parkinson's disease and serotonergic dysfunction: An 11C-WAY 100635 PET study","volume":"60","author":"Doder","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","article-title":"The Parkinson pandemic\u2014A call to action","volume":"75","author":"Dorsey","year":"2018","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2019.06.013_bb0145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainres.2007.05.005","article-title":"The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat","volume":"1158","author":"Dupre","year":"2007","journal-title":"Brain Research"},{"issue":"3","key":"10.1016\/bs.irn.2019.06.013_bb0150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/bs.irn.2019.06.013_bb0155","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.neuroscience.2015.04.027","article-title":"Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease","volume":"298","author":"Fidalgo","year":"2015","journal-title":"Neuroscience"},{"issue":"13","key":"10.1016\/bs.irn.2019.06.013_bb0160","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40265-013-0105-4","article-title":"Non-dopaminergic treatments for motor control in Parkinson's disease","volume":"73","author":"Fox","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/bs.irn.2019.06.013_bb0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00221-018-5390-4","article-title":"Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat","volume":"237","author":"Frouni","year":"2019","journal-title":"Experimental Brain Research"},{"key":"10.1016\/bs.irn.2019.06.013_bb0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fnana.2018.00038","article-title":"Evidence for sprouting of dopamine and serotonin axons in the pallidum of Parkinsonian monkeys","volume":"12","author":"Gagnon","year":"2018","journal-title":"Frontiers in Neuroanatomy"},{"issue":"7","key":"10.1016\/bs.irn.2019.06.013_bb0175","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1007\/s00429-015-1125-5","article-title":"Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys","volume":"221","author":"Gagnon","year":"2016","journal-title":"Brain Structure & Function"},{"issue":"12","key":"10.1016\/bs.irn.2019.06.013_bb0180","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00702-010-0571-8","article-title":"Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"118","author":"Gerlach","year":"2011","journal-title":"Journal of Neural Transmission"},{"issue":"12","key":"10.1016\/bs.irn.2019.06.013_bb0185","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00702-010-0570-9","article-title":"Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"118","author":"Gerlach","year":"2011","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/bs.irn.2019.06.013_bb0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nbd.2015.11.022","article-title":"Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms","volume":"86","author":"Ghiglieri","year":"2016","journal-title":"Neurobiology of Disease"},{"issue":"2","key":"10.1016\/bs.irn.2019.06.013_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Movement Disorders"},{"issue":"6","key":"10.1016\/bs.irn.2019.06.013_bb0200","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys","volume":"15","author":"Gr\u00e9goire","year":"2009","journal-title":"Parkinsonism & Related Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","article-title":"Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease","volume":"510","author":"Halliday","year":"1990","journal-title":"Brain Research"},{"key":"10.1016\/bs.irn.2019.06.013_bb0210","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","article-title":"The highly selective 5-HT 2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l -DOPA-treated parkinsonian marmoset","volume":"139","author":"Hamadjida","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2019.06.013_bb0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jnc.13593","article-title":"Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance","volume":"139","author":"Hernandez","year":"2016","journal-title":"Journal of Neurochemistry"},{"issue":"60","key":"10.1016\/bs.irn.2019.06.013_bb0220","doi-asserted-by":"crossref","first-page":"102705","DOI":"10.18632\/oncotarget.22170","article-title":"Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacological Reviews"},{"issue":"6","key":"10.1016\/bs.irn.2019.06.013_bb0230","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/mds.24964","article-title":"Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease","volume":"27","author":"Huot","year":"2012","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"12","key":"10.1016\/bs.irn.2019.06.013_bb0235","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41580-018-0060-8","article-title":"A new era for understanding amyloid structures and disease","volume":"19","author":"Iadanza","year":"2018","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0240","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1254\/jphs.12003FP","article-title":"Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model","volume":"119","author":"Inden","year":"2012","journal-title":"Journal of Pharmacological Sciences"},{"key":"10.1016\/bs.irn.2019.06.013_bb0245","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neulet.2015.01.064","article-title":"The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein","volume":"590","author":"Jinsmaa","year":"2015","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jnnp-2017-316193","article-title":"Serotonin transporter binding and anxiety symptoms in Parkinson's disease","volume":"89","author":"Joling","year":"2018","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"9996","key":"10.1016\/bs.irn.2019.06.013_bb0255","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"Pt. 1","key":"10.1016\/bs.irn.2019.06.013_bb0260","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2019.06.013_bb0265","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJM198804073181402","article-title":"Uneven pattern of dopamine loss in the striatum of patients with idiopatic Parkinson\u00b4s disease","volume":"318","author":"Kiss","year":"1988","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2019.06.013_bb0270","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/jnnp.54.4.376-a","article-title":"Buspirone in the treatment of levodopa induced dyskinesias","volume":"54","author":"Kleedorfer","year":"1991","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2019.06.013_bb0275","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.nbd.2015.10.021","article-title":"Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC \u03b1-synuclein transgenic rat model of Parkinson's disease","volume":"85","author":"Kohl","year":"2016","journal-title":"Neurobiology of Disease"},{"issue":"5","key":"10.1016\/bs.irn.2019.06.013_bb0280","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/ana.25236","article-title":"Serotonin, \u03b2-amyloid, and cognition in Parkinson disease","volume":"83","author":"Kotagal","year":"2018","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00001756-200301200-00014","article-title":"Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders","volume":"14","author":"Kovacs","year":"2003","journal-title":"Neuroreport"},{"issue":"8","key":"10.1016\/bs.irn.2019.06.013_bb0290","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/dneu.20942","article-title":"Neonatal fluoxetine exposure alters motor performances of adolescent rats","volume":"72","author":"Lee","year":"2012","journal-title":"Developmental Neurobiology"},{"issue":"10","key":"10.1016\/bs.irn.2019.06.013_bb0295","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4088\/JCP.v57n1002","article-title":"Movement disorders associated with the serotonin selective reuptake inhibitors","volume":"57","author":"Leo","year":"1996","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1016\/bs.irn.2019.06.013_bb6500","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1523\/JNEUROSCI.4051-15.2017","article-title":"LRRK2 G2019S Induces Anxiety\/Depression-like behavior before the onset of motor dysfuncion with 5-HT1A receptor upregulation in mice","volume":"38","author":"Lim","year":"2018","journal-title":"Journal of Neuroscience"},{"issue":"6","key":"10.1016\/bs.irn.2019.06.013_bb0300","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: Temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"Journal of Neurochemistry"},{"issue":"20","key":"10.1016\/bs.irn.2019.06.013_bb0305","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.0b013e318292a31d","article-title":"Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD","volume":"80","author":"Loane","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2019.06.013_bb0310","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain"},{"issue":"4","key":"10.1016\/bs.irn.2019.06.013_bb0315","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin2a receptor inverse agonist, for the treatment of Parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2019.06.013_bb0320","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fncel.2017.00274","article-title":"Impairment of serotonergic transmission by the antiparkinsonian drug L-DOPA: Mechanisms and clinical implications","volume":"11","author":"Miguelez","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/bs.irn.2019.06.013_bb0325","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.neuropharm.2012.11.016","article-title":"l-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats","volume":"67","author":"Miguelez","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2019.06.013_bb0330","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fncir.2014.00021","article-title":"Interaction between the 5-HT system and the basal ganglia: Functional implication and therapeutic perspective in Parkinson's disease","volume":"8","author":"Miguelez","year":"2014","journal-title":"Frontiers in Neural Circuits"},{"issue":"13","key":"10.1016\/bs.irn.2019.06.013_bb0335","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/bph.13447","article-title":"The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats","volume":"173","author":"Miguelez","year":"2016","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2019.06.013_bb0340","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nbd.2010.11.007","article-title":"Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease","volume":"41","author":"Navailles","year":"2011","journal-title":"Neurobiology of Disease"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0345","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1471-4159.2011.07292.x","article-title":"Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia","volume":"118","author":"Nevalainen","year":"2011","journal-title":"Journal of Neurochemistry"},{"issue":"S3","key":"10.1016\/bs.irn.2019.06.013_bb0350","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1002\/mds.22062","article-title":"Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease","volume":"23","author":"Obeso","year":"2008","journal-title":"Movement Disorders"},{"issue":"11","key":"10.1016\/bs.irn.2019.06.013_bb0355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11910-017-0794-2","article-title":"PET molecular imaging research of levodopa-induced dyskinesias in Parkinson's disease","volume":"17","author":"Pagano","year":"2017","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"13","key":"10.1016\/bs.irn.2019.06.013_bb0360","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/mds.26326","article-title":"Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity","volume":"30","author":"Paolone","year":"2015","journal-title":"Movement Disorders"},{"issue":"11","key":"10.1016\/bs.irn.2019.06.013_bb0365","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/brain\/awq268","article-title":"Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction","volume":"133","author":"Pavese","year":"2010","journal-title":"Brain"},{"issue":"7","key":"10.1016\/bs.irn.2019.06.013_bb0370","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.26191","article-title":"Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review","volume":"30","author":"Petrou","year":"2015","journal-title":"Movement Disorders"},{"issue":"3","key":"10.1016\/bs.irn.2019.06.013_bb0375","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nbd.2011.05.009","article-title":"Serotonergic mediated body mass index changes in Parkinson's disease","volume":"43","author":"Politis","year":"2011","journal-title":"Neurobiology of Disease"},{"issue":"3","key":"10.1016\/bs.irn.2019.06.013_bb0380","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0385","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","article-title":"Staging of serotonergic dysfunction in Parkinson's disease: An in vivo 11C-DASB PET study","volume":"40","author":"Politis","year":"2010","journal-title":"Neurobiology of Disease"},{"issue":"128","key":"10.1016\/bs.irn.2019.06.013_bb0390","doi-asserted-by":"crossref","first-page":"128ra41","DOI":"10.1126\/scitranslmed.3003391","article-title":"Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts","volume":"4","author":"Politis","year":"2012","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.irn.2019.06.013_bb0395","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.expneurol.2013.06.015","article-title":"Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease","volume":"248","author":"Prinz","year":"2013","journal-title":"Experimental Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2019.06.013_bb0400","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/brain\/awv215","article-title":"Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease","volume":"138","author":"Qamhawi","year":"2015","journal-title":"Brain"},{"issue":"10","key":"10.1016\/bs.irn.2019.06.013_bb0405","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1460-9568.2011.07675.x","article-title":"Brain 5-HT2A receptors in MPTP monkeys and levodopa-induced dyskinesias","volume":"33","author":"Riahi","year":"2011","journal-title":"European Journal of Neuroscience"},{"issue":"7","key":"10.1016\/bs.irn.2019.06.013_bb0410","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuint.2012.08.009","article-title":"Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain","volume":"61","author":"Riahi","year":"2012","journal-title":"Neurochem Int."},{"issue":"5","key":"10.1016\/bs.irn.2019.06.013_bb0415","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2019.06.013_bb0420","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.expneurol.2015.12.005","article-title":"Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT 1A receptors","volume":"277","author":"Sagarduy","year":"2016","journal-title":"Experimental Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0425","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0006-8993(94)91761-2","article-title":"Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects","volume":"639","author":"Shannak","year":"1994","journal-title":"Brain Research"},{"issue":"6645","key":"10.1016\/bs.irn.2019.06.013_bb0430","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.irn.2019.06.013_bb0435","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.114.218966","article-title":"Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus","volume":"351","author":"Stansley","year":"2014","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"17","key":"10.1016\/bs.irn.2019.06.013_bb0440","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1007\/s00213-015-3980-4","article-title":"Behavioral impairments and serotonin reductions in rats after chronic L-dopa","volume":"232","author":"Stansley","year":"2015","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0445","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/toxics3010075","article-title":"L-Dopa and brain serotonin system dysfunction","volume":"3","author":"Stansley","year":"2015","journal-title":"Toxics"},{"issue":"S1","key":"10.1016\/bs.irn.2019.06.013_bb0450","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/mds.22639","article-title":"Clues to how alpha-synuclein damages neurons in Parkinson's disease","volume":"25","author":"Sulzer","year":"2010","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2019.06.013_bb0455","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/brain\/awu409","article-title":"Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: A dose-finding study","volume":"138","author":"Svenningsson","year":"2015","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2019.06.013_bb0460","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2169\/internalmedicine.1359-18","article-title":"Antidepressants for depression, apathy, and gait instability in Parkinson's disease: A multicenter randomized study","volume":"58","author":"Takahashi","year":"2019","journal-title":"Internal Medicine (Tokyo, Japan)"},{"issue":"2","key":"10.1016\/bs.irn.2019.06.013_bb0465","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pnpbp.2012.04.008","article-title":"Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders","volume":"38","author":"Tatara","year":"2012","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"8","key":"10.1016\/bs.irn.2019.06.013_bb0470","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.parkreldis.2015.05.016","article-title":"Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms","volume":"21","author":"Tong","year":"2015","journal-title":"Parkinsonism & Related Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0475","doi-asserted-by":"crossref","first-page":"26285","DOI":"10.1038\/srep26285","article-title":"\u03b1-Synuclein induced toxicity in brain stem serotonin neurons mediated by an AAV vector driven by the tryptophan hydroxylase promoter","volume":"6","author":"Wan","year":"2016","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0480","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1460-9568.2006.04900.x","article-title":"Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein","volume":"24","author":"Wersinger","year":"2006","journal-title":"European Journal of Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2019.06.013_bb0485","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neulet.2009.02.033","article-title":"Partial regulation of serotonin transporter function by gamma-synuclein","volume":"453","author":"Wersinger","year":"2009","journal-title":"Neuroscience Letters"},{"key":"10.1016\/bs.irn.2019.06.013_bb0490","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nicl.2018.03.001","article-title":"Serotonergic dysregulation is linked to sleep problems in Parkinson's disease","volume":"18","author":"Wilson","year":"2018","journal-title":"NeuroImage. Clinical"},{"issue":"4","key":"10.1016\/bs.irn.2019.06.013_bb0495","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/brain\/awu032","article-title":"Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease","volume":"137","author":"Ye","year":"2014","journal-title":"Brain"},{"issue":"6","key":"10.1016\/bs.irn.2019.06.013_bb0500","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.0711839105","article-title":"Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism","volume":"105","author":"Zhang","year":"2008","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2019.06.013_bb0505","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41598-016-0018-z","article-title":"Serotonergic dysfunctions and abnormal iron metabolism: Relevant to mental fatigue of Parkinson disease","volume":"6","author":"Zuo","year":"2016","journal-title":"Scientific Reports"}],"container-title":["International Review of Neurobiology","New Therapeutic Strategies for Brain Edema and Cell Injury"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774219300339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774219300339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:49:49Z","timestamp":1786798189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774219300339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128167540"],"references-count":101,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2019.06.013","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}